Sahba Yazdani
Physician Assistant · Plano, TXNPI 1093190084
Payments from drug & device makers
Across 161 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$484
- Novo Nordisk$342
- Astellas Pharma US Inc$243
- Pfizer$160
- Kowa Pharmaceuticals America, Inc.$158
- GSK$147
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,51494%
- Education$1616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $484 |
| Novo Nordisk | 20 | $342 |
| Astellas Pharma US Inc | 7 | $243 |
| Pfizer | 10 | $160 |
| Kowa Pharmaceuticals America, Inc. | 16 | $158 |
| GSK | 10 | $147 |
| Merck | 7 | $114 |
| Bayer | 6 | $104 |
| Lilly USA, LLC | 6 | $87 |
| Almatica Pharma LLC | 4 | $80 |
| Johnson & Johnson | 6 | $78 |
| Exact Sciences | 4 | $70 |
| Abbott | 5 | $69 |
| Boehringer Ingelheim | 4 | $64 |
| Tris Pharma Inc | 1 | $59 |
| AstraZeneca | 4 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Amgen | 3 | $46 |
| Dexcom, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Vertex | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Si-bone, Inc. | 1 | $14 |
How this compares
$2,675 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $21,218 |
| Testosterone Cypionate | 12 | $571 |
| ProgesteroneProgesterone, Micronized | 18 | $503 |
| Omeprazole | 16 | $459 |
| Atorvastatin Calcium | 30 | $379 |
| Liothyronine Sodium | 11 | $339 |
| Gabapentin | 19 | $223 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $216 |
| Tamsulosin Hcl | 13 | $215 |
| Montelukast Sodium | 16 | $181 |
| Amlodipine Besylate | 15 | $166 |
| Levothyroxine Sodium | 31 | $157 |
| Losartan Potassium | 19 | $141 |
| Zolpidem Tartrate | 24 | $131 |
| Ondansetron Hcl | 12 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $342 | $21,21811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Plano
- Jaime RomanPlano$338K
- Sara FreemanPlano$57K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.